Christopher Melani

1.6k citations

38 papers · 318 indexed · h-index 10

Impact in

Pathology and Forensic Medicine top 5%
- Lymphoma Diagnosis and Treatment
Oncology
- Viral-associated cancers and disorders
- CAR-T cell therapy research

Papers in

Genetics 19
- Chronic Lymphocytic Leukemia Research 19
Pathology and Forensic Medicine 30
- Lymphoma Diagnosis and Treatment 30

Co-authors: Wyndham H. Wilson Mark Roschewski Elaine S. Jaffe Stefania Pittaluga Seth M. Steinberg Kieron Dunleavy Miloš D. Miljković Andrea N. Lucas
Journals: Blood (20 papers)Blood Advances (3 papers)British Journal of Haematology (2 papers)Hematological Oncology (2 papers)Proceedings of the National Academy of Sciences (1 paper)
Partner nations: United States India Ireland

In The Last Decade

Christopher Melani

32 papers receiving 318 citations

Peers

Countries citing papers authored by Christopher Melani

Since Specialization

Citations

This map shows the geographic impact of Christopher Melani's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher Melani with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher Melani more than expected).

Fields of papers citing papers by Christopher Melani

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christopher Melani. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher Melani. The network helps show where Christopher Melani may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Christopher Melani, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Christopher Melani Line = papers co-authored together Christopher Melani links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	An Assessment of Kinase Selectivity, Enzyme Inhibition Kinetics and in Vitro Activity for Several Bruton Tyrosine Kinase (BTK) Inhibitors ACS Pharmacology & Translational Science ·Contemporary Spanish Cinema Studies, Xiaohu Zhang, Patricia Alfonso, Patrick J. Morris, Carleen Klumpp‐Thomas, Christopher Melani, Crystal McKnight, James D. Phelan, David O. Holland, Kelli M. Wilson, Scott B. Hoyt, Stranjae Ivory, Peter J. Tonge, Wyndham H. Wilson, Michele Ceribelli, Louis M. Staudt, Craig J. Thomas	2025	0
2	Response-adapted Phase 2 study of acalabrutinib window prior to frontline chemotherapy in untreated large B-cell lymphoma: Molecular correlates of response to acalabrutinib Blood ·Stranjae Ivory, James D. Phelan, M R. HAYDEN, Christopher Melani, Stefania Pittaluga, D. Dalela, Da Wei Huang, Julius C. Enßle, M.-L. Ancelin, Max J. Gordon, Sarah Evans, Maria Liza Lindenberg, Esther Mena, Elaine S. Jaffe, Louis M. Staudt, Wyndham H. Wilson	2025	0
3	Enitociclib ( VIP152 ), venetoclax and prednisone in relapsed or refractory aggressive non‐Hodgkin lymphoma British Journal of Haematology ·Max J. Gordon, M R. HAYDEN, Stefania Pittaluga, Svetlana Pack, مریم آجورلو, Ahmed Hamdy, Amy J. Johnson, Melanie M. Frigault, Raquel Izumi, Mark Raffeld, Mark Roschewski, Wyndham H. Wilson, Christopher Melani	2025	0
4	Abstract PO-008: Phase I/II study of VIP152 (enitociclib), venetoclax, and prednisone (VVIP) in relapsed/refractory (R/R) lymphoid malignancies Blood Cancer Discovery ·Christopher Melani, Max J. Gordon, M R. HAYDEN, Stefania Pittaluga, Li Chenmeng, Jagan Muppidi, James D. Phelan, Svetlana Pack, Amynah Pradhan, Candis Morrison, Rati Nofrianti, مریم آجورلو, Amy J. Johnson, Melanie M. Frigault, Ahmed Hamdy, Mark Roschewski, Louis M. Staudt, Wyndham H. Wilson	2024	0
5	A Pilot Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (VIPOR) for Diffuse Large B-Cell Lymphoma Involving the Central Nervous System Blood ·D. Dalela, M R. HAYDEN, Christopher Melani, Stefania Pittaluga, James D. Phelan, Jagan Muppidi, Sarah Evans, Amynah Pradhan, Rati Nofrianti, Candis Morrison, Seth M. Steinberg, Elaine S. Jaffe, Louis M. Staudt, Wyndham H. Wilson, Mark Roschewski	2024	1
6	Romidepsin, Azacitidine, Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-Cell Lymphoma Blood ·Max J. Gordon, Miloš D. Miljković, Samuel Y. Ng, M R. HAYDEN, Christopher Melani, Kevin C. Conlon, James D. Phelan, Bonita R. Bryant, Laura M. Yee, Stefania Pittaluga, Elaine S. Jaffe, Louis M. Staudt, Wyndham H. Wilson, Mark Roschewski	2024	2
7	Multi-Component, Time-Course screening to develop combination cancer therapies based on synergistic toxicity Proceedings of the National Academy of Sciences ·Michele Ceribelli, Milton Carlos Kuga, جعفر شاكر احسين, Christopher Melani, Mark Roschewski, Erin Beck, Carleen Maitland, Cody J. Peer, Kelli M. Wilson, Lu Chen, Crystal McKnight, Sam Michael, Zina Itkin, Paul Shinn, William D. Figg, Wyndham H. Wilson, Louis M. Staudt, Craig J. Thomas	2024	2
8	IBCL-297 Phase 2 Study of Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders (LPD) and EBV-Positive Non-Hodgkin Lymphomas (NHL) Clinical Lymphoma Myeloma & Leukemia ·D. Dalela, M R. HAYDEN, Stefania Pittaluga, Jagan Muppidi, Seth M. Steinberg, James D. Phelan, Sarah Evans, Amynah Pradhan, Elaine S. Jaffe, Wyndham H. Wilson, Mark Roschewski, Christopher Melani	2023	1
9	Interferon alfa-2b in patients with low-grade lymphomatoid granulomatosis and chemotherapy with DA-EPOCH-R in patients with high-grade lymphomatoid granulomatosis: an open-label, single-centre, phase 2 trial The Lancet Haematology ·Christopher Melani, Kennichi Dowdell, Stefania Pittaluga, Kieron Dunleavy, Mark Roschewski, Joo Y. Song, Sara Calattini, Jun‐ichi Kawada, A.-L. COLOMB, Pratip K. Chattopadhyay, Mario Roederer, Andrea N. Lucas, Seth M. Steinberg, Elaine S. Jaffe, Jeffrey I. Cohen, Wyndham H. Wilson	2023	1
10	Nivolumab in Lymphomatoid Granulomatosis (LYG) and Other Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders (LPDs) and Non-Hodgkin Lymphomas (NHLs) with Systemic and/or CNS Involvement: Preliminary Analysis of Efficacy and Safety from an Ongoing Phase II Study Blood ·D. Dalela, M R. HAYDEN, Stefania Pittaluga, Jagan Muppidi, James D. Phelan, Amynah Pradhan, Sarah Evans, Candis Morrison, Rati Nofrianti, Seth M. Steinberg, Jeffrey I. Cohen, Elaine S. Jaffe, Wyndham H. Wilson, Mark Roschewski, Christopher Melani	2023	1
11	Phase 1 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide in Combination with Polatuzumab (ViPOR-P) in Relapsed/Refractory B-Cell Lymphoma: Preliminary Analysis of Safety and Efficacy Blood ·Christopher Melani, M R. HAYDEN, Stefania Pittaluga, James D. Phelan, Li Chenmeng, Jagan Muppidi, Craig J. Thomas, Michele Ceribelli, Milton Carlos Kuga, Amynah Pradhan, مریم آجورلو, Seth M. Steinberg, Elaine S. Jaffe, Mark Roschewski, Louis M. Staudt, Wyndham H. Wilson	2022	4
12	Phase 2 Study of Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-Hodgkin Lymphomas Blood ·Szabolcs-D.’avid Kerestes, M R. HAYDEN, Stefania Pittaluga, Jagan Muppidi, James D. Phelan, Sarah Evans, Amynah Pradhan, YokoKato, Seth M. Steinberg, Elaine S. Jaffe, Wyndham H. Wilson, Mark Roschewski, Christopher Melani	2021	8
13	Gene Expression Profiling of Mediastinal Gray Zone Lymphoma and Its Relationship to Primary Mediastinal B-cell Lymphoma and Classical Hodgkin Lymphoma Blood Cancer Discovery ·Stefania Pittaluga, Alina Nicolae, George W. Wright, Christopher Melani, Mark Roschewski, Seth M. Steinberg, C. B. G. Watson, Louis M. Staudt, Elaine S. Jaffe, Wyndham H. Wilson	2020	26
14	Preliminary Results of a Response-Adapted Study of Ibrutinib and Isavuconazole with Temozolomide, Etoposide, Liposomal Doxorubicin, Dexamethasone, Rituximab (TEDDI-R) for Secondary CNS Lymphoma Blood ·Li Chenmeng, Christopher Melani, M R. HAYDEN, Michail S. Lionakis, Stefania Pittaluga, James D. Phelan, Jagan Muppidi, Dorothy I. Biesinger, Matthias Holdhoff, Michael Glantz, John A. Butman, Andrea N. Lucas, Seth M. Steinberg, Elaine S. Jaffe, Louis M. Staudt, Wyndham H. Wilson, Mark Roschewski	2020	5
15	Response-Adapted Therapy in HIV-Associated Diffuse Large B-Cell Lymphoma: Updated Results of a Prospective Phase II Study of Short-Course-EPOCH-RR Blood ·Norihiko Terahara, Mark A. Ahlman, Christopher Melani, Stefania Pittaluga, Kieron Dunleavy, Andrea N. Lucas, Seth M. Steinberg, Elaine S. Jaffe, Wyndham H. Wilson, Mark Roschewski	2019	0
16	Phase 1b Study of Vipor (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide) in Relapsed/Refractory B-Cell Lymphoma: Safety, Efficacy and Molecular Analysis Blood ·Christopher Melani, M R. HAYDEN, Stefania Pittaluga, Miloš D. Miljković, Jagan Muppidi, Craig A. Portell, Rafic Farah, Seung‐Tae Lee, مریم آجورلو, Dorothy I. Biesinger, Seth M. Steinberg, Elaine S. Jaffe, Louis M. Staudt, Mark Roschewski, Wyndham H. Wilson	2019	2
17	Phase II Study of Interferon-Alpha and DA-EPOCH+/-R in Lymphomatoid Granulomatosis Blood ·Christopher Melani, Mark Roschewski, Stefania Pittaluga, Jeffrey I. Cohen, Andrea N. Lucas, Seth M. Steinberg, Elaine S. Jaffe, Wyndham H. Wilson	2018	3
18	End-of-treatment and serial PET imaging in primary mediastinal B-cell lymphoma following dose-adjusted EPOCH-R: a paradigm shift in clinical decision making Haematologica ·Christopher Melani, Ranjana H. Advani, Mark Roschewski, 小野健二, Clara C. Chen, Lucia Baratto, Mark A. Ahlman, Miloš D. Miljković, Seth M. Steinberg, Jessica Lam, Margaret Shovlin, Kieron Dunleavy, Stefania Pittaluga, Elaine S. Jaffe, Wyndham H. Wilson	2018	60
19	Monitoring clinical outcomes in aggressive B-cell lymphoma: From imaging studies to circulating tumor DNA Best Practice & Research Clinical Haematology ·Christopher Melani, Wyndham H. Wilson, Mark Roschewski	2018	6
20	DA-EPOCH-R in Primary Mediastinal B-Cell Lymphoma; Analysis of End of Therapy FDG-PET and Outcome Blood ·Christopher Melani, Ranjana H. Advani, Clara C. Chen, 小野健二, David Venzon, Seth M. Steinberg, Margaret Shovlin, Elaine S. Jaffe, Stefania Pittaluga, Mark Roschewski, Wyndham H. Wilson, Kieron Dunleavy	2016	0

About Christopher Melani

Christopher Melani is a scholar working on Genetics, Pathology and Forensic Medicine, Neurology, Oncology and Cancer Research, having authored 38 papers that have together received 318 indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (30 papers), Chronic Lymphocytic Leukemia Research (19 papers), CNS Lymphoma Diagnosis and Treatment (10 papers), CAR-T cell therapy research (8 papers), Cancer Genomics and Diagnostics (8 papers), Viral-associated cancers and disorders (7 papers), Sarcoma Diagnosis and Treatment (6 papers) and Monoclonal and Polyclonal Antibodies Research (2 papers). The work is most often cited by research in Pathology and Forensic Medicine (263 citations), Oncology (158 citations), Cancer Research (87 citations), Neurology (84 citations) and Genetics (51 citations). Christopher Melani has collaborated with scholars based in United States, India and Ireland. Frequent co-authors include Wyndham H. Wilson, Mark Roschewski, Elaine S. Jaffe, Stefania Pittaluga, Seth M. Steinberg, Kieron Dunleavy, Miloš D. Miljković, Andrea N. Lucas, Louis M. Staudt and Erik Yusko. Their work appears in journals such as Blood, Blood Advances, British Journal of Haematology, Hematological Oncology and Proceedings of the National Academy of Sciences.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact